 HTG Molecular Diagnostics, Inc. HTGM HTG, a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in multiple posters presented by global pharma company partners at the American Association for Cancer Research AACR 2020 Virtual Meeting. We were pleased to see our technology highlighted in two additional abstracts at this years AACR virtual meeting, said Byron Lawson, Senior Vice President and Chief Commercial Officer. It is very satisfying to see our pharma partners enhancing their research and findings with our HTG EdgeSeq technology, and we look forward to continuing to build on this momentum. 